Connect with us

Published

on

As the popularity of semaglutide weight loss medications continues to grow, so does the rate of potentially dangerous overdoses, experts are warning. 

Reported overdoses of semaglutide products such as Ozempic and Wegovy more than doubled between 2022 and 2023, according to Americas Poison Centers in Virginia.

“U.S. Poison Centers have documented 3,316 exposures to products containing semaglutide through Dec. 31, 2023, more than two times the number of cases reported in 2022,” Dr. Kait Brown, clinical managing director of Americas Poison Centers, told Fox News Digital via email.

“These cases include exposures to prescription semaglutide, compounded semaglutide and counterfeit semaglutide,” he said. 

“Most of these cases are associated with accidental therapeutic errors in adults.” Whats causing the overdoses?

Semaglutide medications are intended to be given in a low dose and increased slowly over a four-week period, according to Dr. Seth Kipnis, director of bariatic and robotic surgery at Hackensack Meridian Jersey Shore University Medical Center in Neptune, New Jersey. 7 Reported overdoses of Ozempic and Wegovy doubled between 2022 and 2023, according to Americas Poison Centers in Virginia. REUTERS

“If people jump right to the high dose, they will have more initial negative side effects,” he told Fox News Digital. 

In some cases, people who overdose may be getting the medication from a source other than a local doctor or taking someone else’s prescribed medication, the doctor noted.

People with a semaglutide prescription should follow the manufacturers and prescribing physician’s instructions, Kipnis advised.  7 This photo combo provided by the FDA shows an authentic Ozempic needle, left and a counterfeit needle, right. AP

“The dose is weekly,” he said. “If it is taken daily, it is too much.”

Dr. Maryann Amirshahi, co-medical director of the National Capital Poison Center in Washington, D.C., confirmed that there has been a large overall increase in semaglutide overdoses reported to poison centers nationally. 

“In addition, I have noticed a similar increase at my individual center,” Amirshahi, who is also professor of emergency medicine at the Georgetown University School of Medicine, told Fox News Digital. 7 Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo. REUTERS

The doctor attributes the increase to several factors, chiefly the “huge increase” in semaglutide prescribing.

“Secondarily, it is available in several different forms, which can cause confusion,” Amirshahi noted. 

“Ozempic is a dial-up pen with multiple doses while Wegovy is a single-dose pen.” 7 A person is seen injecting themselves with an Ozempic needle at their home. REUTERS

Another source of confusion is that many people are using compounded products. 

“Compounded versions have their own unique risks when it comes to a potential overdose, especially when theyre dispensed in multi-dose vials,” noted Alyssa Billingsley, PharmD, Missouri-based director of pharmacy content at GoodRx.

“These injections are often dispensed in vials, so theres a greater opportunity for dosing errors since youre measuring out your specific dose with a syringe,” she warned.  7 People who overdose may be getting the medication from a source other than a local doctor or taking someone else’s prescribed medication. REUTERS

“In some cases, the vial may contain as much as 10 times the amount of semaglutide as a single-use injection pen.” Warning signs and symptoms

The most commonly reported overdose symptoms include nausea, vomiting, abdominal pain, dizziness and diarrhea, Brown noted. 

“Some people have reported hypoglycemia (low blood sugar), which can be life-threatening,” she said.

Symptoms of low blood sugar include confusion, tremor, lightheadedness and palpitations, according to Amirshahi. 

“Semaglutide slows stomach emptying, which can lead to nausea, vomiting and abdominal pain,” she said.

In some cases, the stomach becomes almost paralyzed, a condition called gastroparesis, which can lead to dehydration, abnormal electrolytes and kidney damage, said Amirshahi.  7 Pens for the diabetes drug Ozempic sit on a production line. REUTERS

Another potential effect of semaglutide overdose is inflammation of the pancreas. 

“Symptoms of pancreatitis are very similar and can include nausea, vomiting, abdominal pain and dehydration,” Amirshahi noted. 

These signs and symptoms can also occur among patients taking normal doses of the medication as well as in overdoses, she added.

While any drug overdose can be serious, experts noted that taking too much semaglutide is rarely fatal. 

“Semaglutide is generally well-tolerated in overdose compared to other diabities medications,” Amirshahi said.

7 The most common overdose symptoms include nausea, vomiting, abdominal pain, dizziness and diarrhea.  REUTERS

However, for people who develop gastroparesis or pancreatitis, potential complications can include dehydration and kidney damage. 

“While low blood sugar is rare with semaglutide overdose, if it is not detected and treated early, it can lead to seizures,” Amirshahi added.

Kipnis noted that in terms of adverse effects, “anything is possible when an FDA-approved drug is taken inappropriately.” Start your day with all you need to know

Morning Report delivers the latest news, videos, photos and more. Enter your email address

Please provide a valid email address.

By clicking above you agree to the Terms of Use and Privacy Policy.

Thanks for signing up!
Never miss a story. Check out more newsletters What to do in an overdose event

Anyone who is taking a prescribed semaglutide should have a primary care physician or medical provider to provide close follow-up support, especially in the first several weeks as the dose increases, Kipnis advised. 

Although there is no specific antidote for a semaglutide overdose, the primary course of action is to treat the abdominal symptoms with nausea and pain medications, correct electrolytes, and give fluids for dehydration, said Amirshahi.

“We also treat the low blood sugar by giving glucose or dextrose,” she said. “The care is really supportive until the effects of the medication wear off.”

In some cases, it may be possible to manage symptoms at home after consulting with a health care professional, but other situations may require immediate medical attention, Billingsley noted. 

“For example, severe vomiting can result in serious dehydration and electrolyte imbalances, which can be dangerous if left untreated,” she told Fox News Digital. “Severe cases of hypoglycemia can also be life-threatening.”

To prevent an overdose, Billingsley said to make sure you feel comfortable and confident using the injection pen and selecting your specific dose. 

“Understand how often you should be injecting your dose, and consider using alarms, medication reminder apps, or other tools to help keep you on track,” she recommended. “Your pharmacist can be a helpful resource if any questions come up.”

For emergency assistance, call Poison Help at 1.800.222.1222 to speak with a poison expert or visit PoisonHelp.org for support and resources.

When contacted by Fox News Digital regarding the potential for overdoses, Novo Nordisk, maker of Ozempic and Wegovy, provided a statement.

“Novo Nodisk is the only company in the U.S. with FDA-approved products containing semaglutide, identified under the trade names Wegovy, Ozempic and RYBELSUS, and should only be prescribed after a close consultation between a health care provider and a patient and should only be taken under the supervision of a health care provider,” the company said.

It added, “Novo Nordisk stands behind the safety and efficacy of our FDA-approved semaglutide medicines when used as indicated and when taken under the care of a licensed health care professional.”

Continue Reading

Technology

Alibaba posts profit beat as China looks to prop up tepid consumer spend

Published

on

By

Alibaba posts profit beat as China looks to prop up tepid consumer spend

Alibaba Offices In Beijing

Bloomberg | Bloomberg | Getty Images

Chinese e-commerce behemoth Alibaba on Friday beat profit expectations in its September quarter, but sales fell short as sluggishness in the world’s second-largest economy hit consumer spending.

Alibaba said net income rose 58% year on year to 43.9 billion yuan ($6.07 billion) in the company’s quarter ended Sept. 30, on the back of the performance of its equity investments. This compares with an LSEG forecast of 25.83 billion yuan.

“The year-over-year increases were primarily attributable to the mark-to-market changes from our equity investments, decrease in impairment of our investments and increase in income from operations,” the company said of the annual profit jump in its earnings statement.

Revenue, meanwhile, came in at 236.5 billion yuan, 5% higher year on year but below an analyst forecast of 238.9 billion yuan, according to LSEG data.

The company’s New York-listed shares have gained ground this year to date, up more than 13%. The stock fell more than 2% in morning trading on Friday, after the release of the quarterly earnings.

Sales sentiment

Investors are closely watching the performance of Alibaba’s main business units, Taobao and Tmall Group, which reported a 1% annual uptick in revenue to 98.99 billion yuan in the September quarter.

The results come at a tricky time for Chinese commerce businesses, given a tepid retail environment in the country. Chinese e-commerce group JD.com also missed revenue expectations on Thursday, according to Reuters.

Markets are now watching whether a slew of recent stimulus measures from Beijing, including a five-year 1.4 trillion yuan package announced last week, will help resuscitate the country’s growth and curtail a long-lived real estate market slump.

The impact on the retail space looks promising so far, with sales rising by a better-than-expected 4.8% year on year in October, while China’s recent Singles’ Day shopping holiday — widely seen as a barometer for national consumer sentiment — regained some of its luster.

Alibaba touted “robust growth” in gross merchandise volume — an industry measure of sales over time that does not equate to the company’s revenue — for its Taobao and Tmall Group businesses during the festival, along with a “record number of active buyers.”

“Alibaba’s outlook remains closely aligned with the trajectory of the Chinese economy and evolving regulatory policies,” ING analysts said Thursday, noting that the company’s Friday report will shed light on the Chinese economy’s growth momentum.

The e-commerce giant’s overseas online shopping businesses, such as Lazada and Aliexpress, meanwhile posted a 29% year-on-year hike in sales to 31.67 billion yuan.  

Cloud business accelerates

Alibaba’s Cloud Intelligence Group reported year-on-year sales growth of 7% to 29.6 billion yuan in the September quarter, compared with a 6% annual hike in the three-month period ended in June. The slight acceleration comes amid ongoing efforts by the company to leverage its cloud infrastructure and reposition itself as a leader in the booming artificial intelligence space.

“Growth in our Cloud business accelerated from prior quarters, with revenues from public cloud products growing in double digits and AI-related product revenue delivering triple-digit growth. We are more confident in our core businesses than ever and will continue to invest in supporting long-term growth,” Alibaba CEO Eddie Wu said in a statement Friday.

Stymied by Beijing’s sweeping 2022 crackdown on large internet and tech companies, Alibaba last year overhauled the division’s leadership and has been shaping it as a future growth driver, stepping up competition with rivals including Baidu and Huawei domestically, and Microsoft and OpenAI in the U.S.

Alibaba, which rolled out its own ChatGPT-style product Tongyi Qianwen last year, this week unveiled its own AI-powered search tool for small businesses in Europe and the Americas, and clinched a key five-year partnership to supply cloud services to Indonesian tech giant GoTo in September.

Speaking at the Apsara Conference in September, Alibaba’s Wu said the company’s cloud unit is investing “with unprecedented intensity, in the research and development of AI technology and the building of its global infrastructure,” noting that the future of AI is “only beginning.”

Correction: This article has been updated to reflect that Alibaba’s Cloud Intelligence Group reported quarterly revenue of 29.6 billion yuan in the September quarter.

Continue Reading

Technology

Elon Musk’s xAI raising up to $6 billion to purchase 100,000 Nvidia chips for Memphis data center

Published

on

By

Elon Musk's xAI raising up to  billion to purchase 100,000 Nvidia chips for Memphis data center

Elon Musk listens as US President-elect Donald Trump speaks during a House Republicans Conference meeting at the Hyatt Regency on Capitol Hill on November 13, 2024 in Washington, DC. 

Allison Robbert | Getty Images

Elon Musk’s artificial intelligence company xAI is raising up to $6 billion at a $50 billion valuation, according to CNBC’s David Faber.

Sources told Faber that the funding, which should close early next week, is a combination of $5 billion expected from sovereign funds in the Middle East and $1 billion from other investors, some of whom may want to re-up their investments.

The money will be used to acquire 100,000 Nvidia chips, per sources familiar with the situation. Tesla‘s Full Self Driving is expected to rely on the new Memphis supercomputer.

Musk’s AI startup, which he announced in July 2023, seeks to “understand the true nature of the universe,” according to its website. Last November, X.AI released a chatbot called Grok, which the company said was modeled after “The Hitchhiker’s Guide to the Galaxy.” The chatbot debuted with two months of training and had real-time knowledge of the internet, the company claimed at the time.

With Grok, X.AI aims to directly compete with companies including ChatGPT creator OpenAI, which Musk helped start before a conflict with co-founder Sam Altman led him to depart the project in 2018. It will also be vying with Google’s Bard technology and Anthropic’s Claude chatbot.

Now that Donald Trump is President-elect, Elon Musk is beginning to actively work with the new administration on its approach to AI and tech more broadly, as part of Trump’s inner circle in recent weeks.

Trump plans to repeal President Biden’s executive order on AI, according to his campaign platform, stating that it “hinders AI Innovation, and imposes Radical Leftwing ideas on the development of this technology” and that “in its place, Republicans support AI Development rooted in Free Speech and Human Flourishing.”

Continue Reading

Environment

Baidu- and Geely-backed JiYue brand unveils ROBO X EV that goes 0-100 km/h in under 1.9 sec

Published

on

By

Baidu- and Geely-backed JiYue brand unveils ROBO X EV that goes 0-100 km/h in under 1.9 sec

JiYue, a Chinese EV brand focused on delivering all-electric “robocars” to the masses, has unveiled its latest model, and it’s quite a deviation from its previous EVs—but in the best way. Earlier today, JiYue launched the ROBO X supercar, designed for high-speed racing. By high speed, we mean 0-100 km/h acceleration in under 1.9 seconds. My mouth is watering.

JiYue has only existed since 2021, when parent tech company Baidu announced it was expanding from software development into physical EV production, joining forces with multinational automotive manufacturer Geely.

The new “robotic EV” marque initially launched as JIDU with $300 million in startup capital before garnering an additional $400 million in Series A funding, led by Baidu, in January 2022.

In August 2023, Geely took on a larger role in JIDU alongside a greater financial stake as the brand reimagined itself as JiYue, inheriting the JIDU logo and its flagship model, the 01 ROBOCAR.

In December 2023, Baidu and Geely unveiled a second model called the JiYue 07. It was born from JIDU’s ROBO-02 concept, which debuted in 2023 and was designed to compete against the Tesla Model 3 in China.

The 07 finally launched in China earlier this year with 545 miles of range. With an all-electric SUV and sedan on the market, JiYue has unveiled an exciting new entry in the form of a performance supercar called the ROBO X. Check it out:

JiYue’s new ROBO X EV is available for pre-order now

JiYue showcased its new ROBO X hypercar in front of the crowd at the 2024 Guangzhou Auto Show earlier today. Similar to previous models but with a unique spin, JiYue described the ROBO X as an AI smart-driving supercar that, for the first time, blends artificial intelligence and autonomous driving into a high-performance, race-ready EV.

When we say “high performance,” we mean a quad motor liquid-cooled drive system that can propel the ROBO X from 0 to 100 km/h (0 to 62 mph) in under 1.9 seconds. JiYue called the new ROBO X a “performance beast” with “the perfect balance of excellent aerodynamic performance and high downforce.” JiYue CEO Joe Xia was even bolder in his statements about the ROBO X:

For the next 20 years, the design of supercars will bear the shadow of Robo X. This is the best design in the history of Chinese automobiles today, and it is a landmark presence.

Fighter-style airflow ducts bolster the EV’s aerodynamics, efficiency, and overall posture. Per JiYue, the two-seater ROBO X is expected to deliver a maximum range of over 650 km (404 miles).

The new supercar features falcon-wing doors, a carbon fiber integrated frame, and a professional racing HALO safety system offering 360° of support. The interior features an AI smart cockpit with SIMO real-time feedback to give drivers an immersive racing experience.

Furthermore, JiYue said the vehicle will utilize parent company Baidu’s Apollo self-driving technology, which could make it the first electric supercar to apply pure-vision ADAS technology that enables track-level autonomous driving.

Following today’s unveiling of the ROBO X, JiYue has officially opened up pre-orders in China for RMB 49,999 ($6,915). That said, reservation holders will need to be patient as JiYue shared that it doesn’t expect to begin mass production of the ROBO X until 2027.

What do you think? Will people be talking about the ROBO X for the next 20 years?

FTC: We use income earning auto affiliate links. More.

Continue Reading

Trending